Example: routine screening with symptom diagnosis
In mouse studies, measurable effects on organ function appeared within 10-14 days of treatment initiation
Thompson Ray M, Weickert CS, Wyatt E, Webster MJ (2011)
placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD
The combination of products that make up the Lipo-B (MIC) injection are methionine, inositol, choline, and cyanocobalamin (vitamin B12)
Three of the subjects withdrew during the screening period prior to baseline, and sixteen subjects enrolled